HMHuixian Miao

Huixian Miao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Huixian Miao has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism

    by Huixian Miao, Huangyang Meng, Yashuang Zhang, Tian Chen, Lin Zhang, Wenjun Cheng

    Poly ADP-ribose polymerase inhibitors (PARPis) exhibit promising efficacy in patients with BRCA mutations or homologous repair deficiency (HRD) in ovarian cancer (OC). However, less than 40% of patients have HRD, it is vital to expand the indications for PARPis in BRCA-proficient patients. Ferroptosis suppressor protein 1 (FSP1) is a key protein in a newly identified ferroptosis-protective mechanism that occurs in parallel with the GPX4-mediated pathway and is associated with chemoresistance in several cancers. Herein, FSP1 is reported to be negatively correlated with the prognosis in OC patients. Combination therapy comprising olaparib and iFSP1 (a FSP1 inhibitor) strongly inhibited tumour proliferation in BRCA-proficient OC cell lines, patient-derived organoids (PDOs) and xenograft mouse models. Surprisingly, the synergistic killing effect could not be reversed by ferroptosis inhibitors, indicating that mechanisms other than ferroptosis were responsible for the synergistic lethality. In addition, cotreatment was shown to induce increased γH2A.X foci and to impair nonhomologous end joining (NHEJ) activity to a greater extent than did any single drug. Mass spectrometry and immunoprecipitation analyses revealed that FSP1 interacted with Ku70, a classical component recruited to and occupying the end of double-strand breaks (DSBs) in the NHEJ process. FSP1 inhibition decreased Ku70 PARylation, impaired subsequent DNA-PKcs recruitment to the Ku complex at DSB sites and was rescued by restoring PARylation. These findings unprecedentedly reveal a novel role of FSP1 in DNA damage repair and provide new insights into how to sensitize OC patients to PARPi treatment.


  • Open Access

    Pregnancies in women with pulmonary hypertension remain challengeable: a single-center experience from East China

    by Huixian Miao, Yunyan Chen, Chuan Wang, Taotao Huang, Jianhua Lin

    In this study, we aim to find out maternal and fetal outcomes in women with PH resulting from different causes and try to determine the risk factors related to adverse maternal and fetal outcomes. 684 women were included in the final analysis, who were mainly had pulmonary hypertension secondary to congenital heart disease (65.4%). Patients with idiopathic PH have the highest mortality (35.3%) and the lowest live birth rate (82.4%). Mortality is similar between moderate and severe PH women(5.3% vs 9.7%, P=0.17), but live birth rate is much lower in severe PH women (78.6% vs 89.9%, P<0.01). The overall mortality was 2.8%, decreasing from 6.6% (4/61) in 2001~2005 to 1.7% (4/235) in 2016~2020 (P=0.10). Hypoxemia and vaginal birth are risk factors of maternal death both in the univariate analysis [OR 13.49(5.15-35.31), OR 4.16(1.52-11.42), respectively] and multivariate analysis [35.28 (1.42-878.75), 850.86 (5.67-127606.74), respectively]. General anesthesia is a risk factor in the univariate analysis [OR 12.07(3.72-39.15)] but with no significance in the multivariate analysis (P=0.16). We demonstrate a lower mortality rate than previously reported, although of no statistical difference among years in our center. In PH secondary to connective tissue disease and idiopathic PH, maternal mortality remains high. Maternal and fetal outcome are related to the etiology and the severity of PASP. Hypoxemia is a risk factor of maternal death while cesarean section seems to be a protective factor. The ideal choice of anesthesia remains uncertain. PH-targeted drugs cannot effectively decrease mortality rate. Thus, pregnancies remain challengeable in PH women.

  • Preoperative hysteroscopy shortened progression‐free survival in advanced FIGO stage in endometrial cancer: Ten year analysis

    by Huixian Miao, Lin Zhang, Yi Jiang, Yicong Wan, Lin Yuan, Wenjun Cheng

    Objective: To investigate the impact of preoperative hysteroscopy on progression‐free survival (PFS) and disease‐specific survival (DFS), and to explore the factors which contribute to poor clinical outcomes between hysteroscopy and dilation and curettage (D&C) in endometrial cancer (EC).Methods: A retrospective study was designed by collecting data from women diagnosed with EC through hysteroscopy or D&C from January 2010 to December 2019 in a tertiary hospital in China. A propensity score was used for 1:1 matching of advanced stage patients. Univariate and multivariate analysis were conducted to determine whether hysteroscopy was a prognostic factor in EC and to identify factors associated with its impact on PFS and DFS in different subgroups.Results: Overall, 543 and 272 women who underwent D&C and hysteroscopy, respectively were included. Compared to D&C, preoperative hysteroscopy was related to reduced PFS and DFS, with a hazard ratio (HR) of 1.904 and 3.905, respectively. Hysteroscopy contributed to an increased risk of positive wash cytology (48.27% vs 24.13%), recurrence (48.28% vs 20.69%) and shorter PFS after matching in FIGO Stage I–IV EC, while there was no significance in positive ascites cytology (14.04% vs 13.45%), PFS and DFS in FIGO Stage I EC.Conclusions: Hysteroscopy was an independent predictive factor for poor prognosis in EC. Hysteroscopy appeared to be a safe diagnostic method as D&C in FIGO Stage I EC but was a risk factor for increased recurrence and reduced PFS in advanced stage disease. Its impact on DFS is uncertain.


  • Pregnancies in women with moderate and severe pulmonary hypertension remain challenging: A single‐center experience in East China

    by Huixian Miao, Yunyan Chen, Chuan Wang, Taotao Huang, Jianhua Lin

    Objective: To determine the outcomes in women with pulmonary hypertension (PH) and determine the factors related to adverse outcomes.Methods: Data from 684 women with PH admitted to the Affiliated Renji Hospital from January 2001 to December 2020 were collected. Outcomes were compared based on the causes and severity of PH.Results: The overall mortality was 2.8%, decreasing from 6.6% in 2001–2005 to 1.7% in 2016–2020 (P = 0.10). Idiopathic PH had the highest mortality (35.3%) and the lowest live birth rate (82.4%). Mortality was similar between moderate and severe PH (5.3% versus 9.7%), but the live birth rate was much lower in severe PH (78.6% versus 89.9%). Hypoxemia and vaginal birth were risk factors of maternal death (odds ratio [OR] 35.28, 95% confidence interval [CI] 1.42–878.75; OR 850.86, 95% CI 5.67–127 606.74, respectively). General anesthesia was a risk factor in the univariate analysis (OR 12.07, 95% CI 3.72–39.15) but was not significant in the multivariate analysis (P = 0.16).Conclusion: The mortality rate in this retrospective study was lower than that previously reported. Pregnancy is safe in mild PH but still has a high risk of complications in moderate and severe PH. Hypoxemia is a risk factor for maternal death, but cesarean section may be a protective factor.


  • Open Access

    Outcome of pregnancies in pregnant women with pulmonary hypertension: a single-center experience from East China

    by Huixian Miao, Jianhua Lin, Yunyan Chen, Chuan Wang, Taotao Huang

    In this study, we aim to find out maternal and fetal outcomes in women with PH resulting from different causes and try to determine the risk factors related to adverse maternal and fetal outcomes. We extracted the data from the records: the demographic information, onset, course, clinical and echocardiographic details, maternal and fetal complications, management as well as obstetric data, which included complications, infant of low-birth weight. We compared the outcome based on the cause of disease and pulmonary hypertension pressure levels. 603 women were included in the final analysis, who were mainly had pulmonary hypertension secondary to congenital heart disease (66.0%) and 46 of whom had Eisenmenger syndrome (7.6%). The mortality was 3.0%, 56% of which was caused by Eisenmenger syndrome. The abortion rate was 8.3% and 32% of live newborns were born before term. Heart failure complicated 17.1% and fetal growth restriction 3.5% of pregnancies. Advanced medication was administered in an increasing number of patients. Morbidity was significantly increased in women with pulmonary hypertension associated with a pulmonary hypertension pressure ≥80 mmHg. The mortality rate was lower than previously reported. Nevertheless, in Eisenmenger syndrome, PH secondary to connective tissue disease and idiopathic PH, the maternal mortality is still very high. In addition to the use of PAH-targeted drugs, we believe that standardized maternal management strategies can also help reduce mortality, including screening for heart disease and effective transport of critically ill patients. The maternal and infant outcome is related to etiology and the severity of PASP.